{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:37Z","timestamp":1790982997272,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,15]]},"DOI":"10.7759\/cureus.114566","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:50:15Z","timestamp":1786805415000},"source":"Crossref","is-referenced-by-count":1,"title":["Maribavir for the Management of a Complex Cytomegalovirus (CMV) Infection After Liver Transplantation: Refractoriness and Intolerance to Standard Therapies in the Intensive Care Unit"],"prefix":"10.7759","author":[{"given":"Laura","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"In\u00e1cio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cochicho Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim\u00e3o C","family":"Rodeia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Germano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-012-0292-2","article-title":"Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment","volume":"14","author":"Beam E","year":"2012","unstructured":"Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep. 2012, 14:633-41. 10.1007\/s11908-012-0292-2","journal-title":"Curr Infect Dis Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000433","article-title":"Cytomegalovirus in liver transplant recipients","volume":"22","author":"Herman D","year":"2017","unstructured":"Herman D, Han H. Cytomegalovirus in liver transplant recipients. Curr Opin Organ Transplant. 2017, 22:345-50. 10.1097\/MOT.0000000000000433","journal-title":"Curr Opin Organ Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00557-6","article-title":"Moving past ganciclovir and foscarnet: advances in CMV therapy","volume":"15","author":"Hakki M","year":"2020","unstructured":"Hakki M. Moving past ganciclovir and foscarnet: advances in CMV therapy. Curr Hematol Malig Rep. 2020, 15:90-102. 10.1007\/s11899-020-00557-6","journal-title":"Curr Hematol Malig Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain NS","year":"2010","unstructured":"Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010, 23:689-712. 10.1128\/CMR.00009-10","journal-title":"Clin Microbiol Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241237534","article-title":"Cytomegalovirus treatment in solid organ transplantation: an update on current approaches","volume":"58","author":"Hardinger KL","year":"2024","unstructured":"Hardinger KL, Brennan DC. Cytomegalovirus treatment in solid organ transplantation: an update on current approaches. Ann Pharmacother. 2024, 58:1122-33. 10.1177\/10600280241237534","journal-title":"Ann Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman P","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, et al.. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024, 79:787-94. 10.1093\/cid\/ciae321","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13696","article-title":"Maribavir: mechanism of action, clinical, and translational science","volume":"17","author":"Sun K","year":"2024","unstructured":"Sun K, Fournier M, Sundberg AK, Song IH. Maribavir: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024, 17:e13696. 10.1111\/cts.13696","journal-title":"Clin Transl Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial","volume":"75","author":"Avery RK","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, et al.. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial. Clin Infect Dis. 2022, 75:690-701. 10.1093\/cid\/ciab988","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou GA","year":"2024","unstructured":"Papanicolaou GA, Avery RK, Cordonnier C, et al.. Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis. 2024, 78:562-72. 10.1093\/cid\/ciad709","journal-title":"Clin Infect Dis"},{"key":"ref10","article-title":"Antiviral drug-induced nephrotoxicity","volume":"20","author":"Neto R","year":"2007","unstructured":"Neto R, Oliveira G, Pestana M. Antiviral drug-induced nephrotoxicity. Acta Med Port. 2007, 20:59-63.","journal-title":"Acta Med Port"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae094","article-title":"Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient","volume":"79","author":"Luque-Paz D","year":"2024","unstructured":"Luque-Paz D, Lalanne S, Besombes J, Dorel M, Maamar A, Revest M. Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient. J Antimicrob Chemother. 2024, 79:1462-3. 10.1093\/jac\/dkae094","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a Phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou S","year":"2024","unstructured":"Chou S, Alain S, Cervera C, et al.. Drug resistance assessed in a Phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. J Infect Dis. 2024, 229:413-21. 10.1093\/infdis\/jiad293","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.02.093","article-title":"Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases","volume":"41","author":"Ar MC","year":"2009","unstructured":"Ar MC, Ozbalak M, Tuzuner N, et al.. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. Transplant Proc. 2009, 41:1648-53. 10.1016\/j.transproceed.2009.02.093","journal-title":"Transplant Proc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/513202-maribavir-for-the-management-of-a-complex-cytomegalovirus-cmv-infection-after-liver-transplantation-refractoriness-and-intolerance-to-standard-therapies-in-the-intensive-care-unit","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:50:16Z","timestamp":1786805416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/513202-maribavir-for-the-management-of-a-complex-cytomegalovirus-cmv-infection-after-liver-transplantation-refractoriness-and-intolerance-to-standard-therapies-in-the-intensive-care-unit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.114566","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,15]]}}}